- Home
- PRAX vs HALO Comparison
PRAX vs HALO Comparison
Compare PRAX & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | HALO |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.5B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRAX | HALO |
|---|---|---|
| Price | $302.65 | $71.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $397.85 | $76.42 |
| AVG Volume (30 Days) | 569.5K | ★ 1.8M |
| Earning Date | 02-27-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | N/A | ★ 4.74 |
| Revenue | $7,463,000.00 | ★ $1,242,852,000.00 |
| Revenue This Year | N/A | $34.54 |
| Revenue Next Year | $14,827.76 | $26.28 |
| P/E Ratio | ★ N/A | $15.41 |
| Revenue Growth | ★ 364.98 | 31.19 |
| 52 Week Low | $26.70 | $47.50 |
| 52 Week High | $317.72 | $79.50 |
Technical Indicators
Market Signals| Indicator | PRAX | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 63.66 | 55.62 |
| Support Level | $266.93 | $71.18 |
| Resistance Level | $306.16 | $74.08 |
| Average True Range (ATR) | 16.00 | 2.07 |
| MACD | -2.36 | 0.21 |
| Stochastic Oscillator | 71.06 | 51.34 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.